Tinostamustine Dual-Function Therapy for T-PLL DNA Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective chemotherapeutic treatments for T-cell prolymphocytic leukemia (T-PLL), as conventional chemotherapy offers a poor prognosis with a median survival of around 7 months, and existing treatments like alemtuzumab have limited efficacy and are no longer available.
Innovation Solution
Tinostamustine or a pharmaceutically acceptable salt thereof is administered to patients with T-PLL, providing strong in vitro and in vivo sensitivity, effectively inhibiting the HDAC pathway and inducing DNA damage in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat T-PLL, then treatment can be administered, but patient survival is poor with median survival of around 7 months
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using tinostamustine, a dual-functional alkylating-HDACi fusion molecule with specific molecular structure (formula I), instead of conventional chemotherapy agents. This parameter change in the drug molecule enables simultaneous HDAC inhibition and DNA alkylation, improving treatment efficacy and survival outcomes compared to conventional chemotherapy
Solution Approach 2:
Tinostamustine is a composite molecular structure combining two distinct functional moieties: an HDAC inhibitor component and an alkylating agent component. This composite structure allows the single molecule to perform dual functions (HDAC inhibition and DNA alkylation) that were previously achieved only through combination therapies, thereby improving treatment reliability and patient survival
2Reliability
If alemtuzumab is used to treat T-PLL, then remission can be induced, but relapse occurs and the drug is no longer available
Solution Approach 1:
The patent transitions from using alemtuzumab (a monoclonal antibody with specific immunological mechanism) to tinostamustine (a small molecule with dual alkylating-HDACi activity). This parameter change in the therapeutic agent provides sustained remission through DNA damage and epigenetic modification mechanisms that prevent relapse, addressing the durability issue with alemtuzumab
Solution Approach 2:
Tinostamustine exploits the T-PLL cells' dependence on HDAC activity and DNA repair mechanisms by introducing a dual-functional agent that simultaneously inhibits HDAC and alkylates DNA. This converts the cancer cells' reliance on specific survival pathways into their vulnerability, inducing sustained remission and preventing relapse
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Tinostamustine demonstrates potent cytotoxicity against T-PLL cells, inducing a robust DNA damage response and apoptosis, even in the presence of stromal cell protection, with a dosage range of 0.3 mg/m2 to 300 mg/m2 body surface area, preferably intravenously.
Implementation Method 1
Tinostamustine demonstrates potent cytotoxicity against T-PLL cells, inducing a robust DNA damage response and apoptosis
Implementation Method 2
effectively inhibiting the HDAC pathway and inducing DNA damage in cancer cells
Data Source
AI summary
There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.